Search research articles
Contact Us
Filters
Showing results (51-60 of 78) with videos related to
Page
of 8
Sort By:
Transplantation Proceedings
|
December 17, 2011
Anti-Gal titers in healthy adults and inflammatory bowel disease patients
A Mangold, D Lebherz, P Papay, et al.
The American Journal of Gastroenterology
|
August 13, 1999
Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse
W Reinisch, C Gasché, W Tillinger, et al.
Journal of Crohn'S & Colitis
|
June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease
S Schreiber, W Reinisch, J F Colombel, et al.
Alimentary Pharmacology & Therapeutics
|
September 19, 2015
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
B Jharap, W J Sandborn, W Reinisch, et al.
Journal of Clinical Immunology
|
November 27, 2001
Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries
E Jensen-Jarolim, C Neumann, G Oberhuber, et al.
Zeitschrift Fur Gastroenterologie
|
March 29, 2011
[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]
W Reinisch, C Dejaco, T Feichtenschlager, et al.
Alimentary Pharmacology & Therapeutics
|
May 22, 2015
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
M Rosario, N L Dirks, M R Gastonguay, et al.
Alimentary Pharmacology & Therapeutics
|
September 18, 2012
Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors
P Papay, C Primas, A Eser, et al.
Alimentary Pharmacology & Therapeutics
|
December 8, 2011
The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's disease
A Eser, P Papay, C Primas, et al.
Journal of Crohn'S & Colitis
|
December 3, 2010
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease
W Miehsler, G Novacek, H Wenzl, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 78) with videos related to
Sort By:
Page
of 8
Transplantation Proceedings
|
December 17, 2011
Anti-Gal titers in healthy adults and inflammatory bowel disease patients
A Mangold, D Lebherz, P Papay, et al.
The American Journal of Gastroenterology
|
August 13, 1999
Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse
W Reinisch, C Gasché, W Tillinger, et al.
Journal of Crohn'S & Colitis
|
June 19, 2012
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease
S Schreiber, W Reinisch, J F Colombel, et al.
Alimentary Pharmacology & Therapeutics
|
September 19, 2015
Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
B Jharap, W J Sandborn, W Reinisch, et al.
Journal of Clinical Immunology
|
November 27, 2001
Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries
E Jensen-Jarolim, C Neumann, G Oberhuber, et al.
Zeitschrift Fur Gastroenterologie
|
March 29, 2011
[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]
W Reinisch, C Dejaco, T Feichtenschlager, et al.
Alimentary Pharmacology & Therapeutics
|
May 22, 2015
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
M Rosario, N L Dirks, M R Gastonguay, et al.
Alimentary Pharmacology & Therapeutics
|
September 18, 2012
Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors
P Papay, C Primas, A Eser, et al.
Alimentary Pharmacology & Therapeutics
|
December 8, 2011
The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's disease
A Eser, P Papay, C Primas, et al.
Journal of Crohn'S & Colitis
|
December 3, 2010
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease
W Miehsler, G Novacek, H Wenzl, et al.
Page
of 8